Home > Insider Trading > Filing (0001567619-19-012282)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1676725	Ideaya Biosciences Inc.	IDYA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1240357	D John Diekman	C/O 5Am Ventures 501 Second Street, Suite 350 San Francisco CA 94107		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-05-28	1,721,898	$0.00	2,026,098	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2019-05-28	578,447	$0.00	2,604,545	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2019-05-28	71,745	$0.00	84,420	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2019-05-28	24,101	$0.00	108,521	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2019-05-28	240,000	$10.00	2,844,545	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2019-05-28	10,000	$10.00	118,521	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2019-05-28	1,721,898	$0.00	1,721,898	$0.00
Common Stock	Series B Preferred Stock	Disposition	2019-05-28	578,447	$0.00	578,447	$0.00
Common Stock	Series A Preferred Stock	Disposition	2019-05-28	71,745	$0.00	71,745	$0.00
Common Stock	Series B Preferred Stock	Disposition	2019-05-28	24,101	$0.00	24,101	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.
Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
The shares are held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Dr. Diekman disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
The shares are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Dr. Diekman disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.